---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093348"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:13:12.664830+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1

## Summary
- Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.
- PGN-EDO51 (DMD) 5mg/kg cohort: mean exon skipping 2.15%, dystrophin increase 0.70% (muscle-adjusted) from baseline; well tolerated.
- FREEDOM-DM1 Phase 1 results expected Q4 2024; FREEDOM2-DM1 cleared by Health Canada & MHRA, dosing H2 2024.
- PGN-EDO53 (DMD) advancing in IND/CTA-enabling studies.

## SEC filing metadata
- accession: 0000950170-24-093348
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/0000950170-24-093348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/pepg-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093348
- JSON: https://secwatch.observer/filing/0000950170-24-093348.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.